Back to Awarded Treatment Trials
Awarded Trial: 01T-435
Grant ID
01T-435
Illness
Bipolar Disorder and Schizophrenia
Primary Drug/Intervention
Trimethoprim-sulfamethoxazole
Primary Dosage
400 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Li
Sample Size
1500
Duration of Study Period for Each Subject
18 months
Outcome Measurements
PANSS, BPRS, HAMD, YMRS
Results
Six hundred patients with first episode schizophrenia were screened. Ninety-nine of them were seropositive for toxoplasmosis (16.5%), which was a rate higher than that seen in normal controls (5.5%), affective disorders (11.8%) or ?physical diseases? (6.0%). These 99 patients were randomized to receive Bactrim or placebo in addition to risperidone. The investigators used 50% reduction in total PANSS scores as the final outcome measure. Eighty-five percent of patients in the Bactrim group and 69% of the patients in the placebo group achieved this criterion. This just missed statistical significance (p=0.059).
Publication
N/A
Link
N/A
PI Name
Qiuying Li
Degree
MD
Center
People's Hospital of Wuhan University
Institution
Renmin Hospital of Wuhan University
Address
Jiefang Road # 238
City or Town
Wuchang
State or Province
Wuhan
Zip or Postal Code
430060
Country
China
Email Address
huilingwt@163.net